120355-79-5

Upstream product

• 26153-38-8 3,5-dihydroxybenzaldehyde 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 

Downstream Products

• 277319-04-7 methyl (RS)-(4-cyano-phenylamino)-(3,5-diethoxy-phenyl)-acetate 
• 188813-38-9 ethyl-3-amino-3-(3,5-diethoxyphenyl)-propionate 
• 1044284-83-4 N-(5-((1R,2S)-2-(3,5-Diethoxybenzylamino)-1-hydroxypropyl)-2-hydroxyphenyl)methanesulfonamide 
• 198623-56-2 3,5-diethoxybenzyl alcohol 
• 1226764-56-2 2α-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-54-0 2α-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-53-9 2α-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-55-1 2α-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-51-7 C₆₂H₁₁₁NO₈Si₄ 
• 1226764-47-1 2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-46-0 C₆₂H₁₁₁NO₇Si₄ 
• 1226764-43-7 2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-41-5 2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 
• 1226764-40-4 2α-methyl-1α,25-dihydroxyvitamin D3-26,23-lactam-N-(3,5-diethoxybenzyl) 

Relevant academic research and scientific papers

In vitro study and structure-activity relationship analysis of stilbenoid derivatives as powerful vasorelaxants: Discovery of new lead compound

The development of vasorelaxant as the antihypertensive drug is important as it produces a rapid and direct relaxation effect on the blood vessel muscles. Resveratrol (RV), as the most widely studied stilbenoid and the lead compound, inducing the excellent vasorelaxation effect through the multiple signalling pathways. In this study, the in vitro vascular response of the synthesized trans-stilbenoid derivatives, SB 1-8e were primarily evaluated by employing the phenylephrine (PE)-precontracted endothelium-intact isolated aortic rings. Herein we report trans-3,4,4′-trihydroxystilbene (SB 8b) exhibited surprisingly more than 2-fold improvement to the maximal relaxation (Rmax) of RV. This article also highlights the characterization of the aromatic protons in terms of their unique splitting patterns in 1H NMR.

RENIN INHIBITORS

The invention provides compounds, pharmaceutical compositions, kits, method of preparing, and method of using the compounds which exhibit renin and other S9 proteases activities and consist of the formula:—wherein the variables are as defined herein.

New blood coagulation factor inhibitors

The invention relates to novel compounds with formula (I) wherein R1-R7 are as herein defined useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIA, Factor VII variants, or Factor VII derivatives.

PYRIMIDINE AND QUINAZOLINE DERIVATIVES

This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES

This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES

This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES

This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES

This invention is concerned with compounds of the formula (I) wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical

Pyrimidine, quinazoline, pteridine and triazine derivatives

This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Design of potent PPARα agonists

Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARα agonists. Optimum PPARα potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPARα potency of 0.002 μM and a selectivity ratio to PPARγ and PPARδ of 410 and 2000, respectively.